Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis.
about
Maspin is a tumour suppressor that inhibits breast cancer tumour metastasis in vivoUrokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivoProbing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor.Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer.Fibrin turnover in lung inflammation and neoplasia.The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis.Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissueReceptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice.Early breast cancer screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of detection.Reactive oxygen species regulate urokinase plasminogen activator expression and cell invasion via mitogen-activated protein kinase pathways after treatment with hepatocyte growth factor in stomach cancer cells.Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.Aeroallergen Der p 2 promotes motility of human non-small cell lung cancer cells via toll-like receptor-mediated up-regulation of urokinase-type plasminogen activator and integrin/focal adhesion kinase signaling.Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.Rac1-MKK3-p38-MAPKAPK2 pathway promotes urokinase plasminogen activator mRNA stability in invasive breast cancer cells.Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells.Inhibitory effects of retinoic acid on invasiveness of human thyroid carcinoma cell lines in vitro.The fibrinolytic system facilitates tumor cell migration across the blood-brain barrier in experimental melanoma brain metastasis.High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells.Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity.Challenges for drug discovery - a case study of urokinase receptor inhibitionTime-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.Alpha(v) integrin, p38 mitogen-activated protein kinase, and urokinase plasminogen activator are functionally linked in invasive breast cancer cells.Oxygen-mediated regulation of tumor cell invasiveness. Involvement of a nitric oxide signaling pathway.Novel molecular mechanisms of dendritic cell-induced T cell activation.
P2860
Q24802539-32EF3596-203B-489B-8628-9977964BFBDFQ28350698-C60E17CB-FA67-432A-AAFD-D45152C827BDQ33758094-01780206-E980-4F96-9802-937ED9DFD214Q34075406-16F42D49-738D-459B-A3EF-594D226D3BDFQ34141236-E81821AC-08C5-4854-ACD5-5C72D16BE586Q34165118-9BE5362C-25E7-4FF4-B020-0E6346495943Q35745789-CE818E6F-22D7-4971-B05E-5EE3D946C31BQ35764327-C15E621D-8BD6-4166-9812-4D2C3F4FA1DCQ36254926-6934FC44-B15E-4145-B93C-5E624987AB21Q36991435-DC8B49EA-DF07-445D-9CE0-7430C3E52D6FQ37233640-54703424-04A4-44E6-85E6-BE36DFDF7A00Q37336713-985C5D0B-FEDE-422D-B445-FC2F0E0FF9F2Q37706905-CD8FA5D3-65C4-4D9F-A6DB-D9C261C596E8Q38308022-320C7964-C278-4149-A76D-1DD7ADFDF4CDQ38362019-F7F58351-3416-43B6-B240-9612E5A8563DQ38601915-E5EA0823-DB0D-4D0D-985C-F20FC1C48A01Q39840396-6197D8E8-0B6D-4D23-A73B-1C2B989AEAC2Q40307552-21A819B4-D9F9-4644-9576-CFFA1A412876Q40784517-AA8FB027-CF15-4610-9E03-F3FCA62B3679Q40863969-F33E7B93-0481-4B5A-8A47-1E4A055CE07CQ40886640-D82B9191-89F3-4B51-820F-2BDA3FF3FF04Q41908264-0FC40B94-944E-4C16-A957-D63BD13D420DQ41912805-36A97EE1-5C96-4FFF-B9E3-B56FD8A82E26Q43770510-597FDDF2-1318-4086-AFC9-C81C7B0E2C06Q44055074-F1F4A55A-4AC7-415D-8FC1-94B6DD9C8D25Q52026093-9D9681B9-EEC3-47BE-A377-4AB373231B9E
P2860
Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Overexpression of urokinase re ...... vasion, growth and metastasis.
@en
type
label
Overexpression of urokinase re ...... vasion, growth and metastasis.
@en
prefLabel
Overexpression of urokinase re ...... vasion, growth and metastasis.
@en
P2860
P1476
Overexpression of urokinase re ...... vasion, growth and metastasis.
@en
P2093
P2860
P304
P356
10.1002/(SICI)1097-0215(19960729)67:3<423::AID-IJC18>3.0.CO;2-8
P577
1996-07-01T00:00:00Z